A New Line of Sight Into
Targeted Cancer Therapies
Developing a Novel Class of Targeted
Alpha-Particle Radiopharmaceuticals
We are an alpha-particle radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.
Our new, proprietary class of theranostics enable the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
Theranostics:
Understanding Which Patients Will Respond to Therapy
See the Tumor – Determine patient response, image tumor and identify tumor location
Treat the Tumor – Demonstrated to kill cancer cells with the ability to optimize patient dosing based on diagnostic images
Development Pipeline
Latest News:
Viewpoint Molecular Targeting® Announces Publication of Preclinical Data of VMT01 in Peer-Reviewed Journal, “Cancers”
Viewpoint Molecular Targeting® Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
Viewpoint Molecular Targeting® to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Presentations:
Get Notified:
Let us keep you up to date on news and information
Contact Us:
Viewpoint Molecular
Targeting, Inc.
2500 Crosspark Rd
Coralville, IA 52241
info@viewpointmt.com
(865) 356-1861
Investor Relations
JTC Team, LLC
Jenene Thomas
viewpoint@jtcir.com
(833) 475-8247